Johnson & Johnson (NYSE:JNJ) Shares Acquired by Avitas Wealth Management LLC

Avitas Wealth Management LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,721 shares of the company’s stock after purchasing an additional 1,148 shares during the quarter. Johnson & Johnson makes up 0.9% of Avitas Wealth Management LLC’s portfolio, making the stock its 24th largest holding. Avitas Wealth Management LLC’s holdings in Johnson & Johnson were worth $5,599,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. O ROURKE & COMPANY Inc grew its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. O ROURKE & COMPANY Inc now owns 9,199 shares of the company’s stock worth $1,442,000 after acquiring an additional 69 shares during the last quarter. SteelPeak Wealth LLC boosted its stake in Johnson & Johnson by 52.6% during the 4th quarter. SteelPeak Wealth LLC now owns 52,364 shares of the company’s stock valued at $8,208,000 after purchasing an additional 18,051 shares during the period. Compass Ion Advisors LLC boosted its stake in Johnson & Johnson by 0.9% during the 4th quarter. Compass Ion Advisors LLC now owns 14,978 shares of the company’s stock valued at $2,348,000 after purchasing an additional 135 shares during the period. Comprehensive Financial Consultants Institutional Inc. increased its stake in shares of Johnson & Johnson by 5.0% in the fourth quarter. Comprehensive Financial Consultants Institutional Inc. now owns 21,685 shares of the company’s stock valued at $3,399,000 after purchasing an additional 1,026 shares during the period. Finally, Breakwater Capital Group raised its holdings in shares of Johnson & Johnson by 2.8% during the fourth quarter. Breakwater Capital Group now owns 6,919 shares of the company’s stock valued at $1,124,000 after buying an additional 191 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $152.31 on Wednesday. The company has a 50-day moving average of $157.79 and a two-hundred day moving average of $156.18. The stock has a market cap of $367.03 billion, a price-to-earnings ratio of 11.03, a PEG ratio of 2.56 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period in the previous year, the firm earned $2.35 earnings per share. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Finally, Raymond James boosted their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Insider Activity

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.